Need for better screening tools and tests to better determine which women benefit from mammography, ultrasound or MRI screening:

• Development of a “Breast Fluid Test” to identify women at risk for breast cancer who would benefit from routine screening – Susan Love, MD, Dr. Susan Love Research Foundation
• Biomarkers for early breast cancer detection in women with mammographically occult breast cancer – Emanuel (Chip) Petricoin, PhD, George Mason University
• Development of a GP88 serum test for early breast cancer diagnosis – Ginette Serrero, PhD, A&G Pharmaceutical
• Validation of an autoantibody signature for breast cancer – Sam Hanash, MD, PhD, Fred Hutchinson Cancer Research Center
• Identifying salivary biomarkers for breast cancer detection - Charles Streckfus, DDS, MA, FAOM, University of Texas Health Sciences Center at Houston
• Development of Biomarkers for Breast Cancer from Urine Samples Using 2-D NOESY NMR – Mary McCourt, PhD, Niagara University
• ACRIN-6666 Clinical Trial, a trial evaluating breast ultrasound, mammography, and MRI as screening tools in high risk women – Wendie Berg, MD, PhD, American College of Radiology Imaging Network

Need to learn which women diagnosed at an early stage need aggressive treatment and which might benefit from watchful waiting:

• Molecular markers that predict future formation of malignant breast cancer – Thea Tlsty, PhD, University of California San Francisco
• Characterizing variation in tissue markers in the breast cancer microenvironment – Melissa Troester, PhD, University of North Carolina Chapel Hill
• Gene methylation and estradiol levels in random FNA samples as biomarkers of breast cancer risk – Sara Sukumar, PhD, Johns Hopkins and Seema Khan, MD, Northwestern University
• Enhancer of Zeste2 as a biomarker of preneoplastic progression in the breast – Celina Kleer, MD, University of Michigan